These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28719013)

  • 21. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.
    Ciaccio A; Cortesi PA; Bellelli G; Rota M; Conti S; Okolicsanyi S; Rota M; Cesana G; Mantovani LG; Annoni G; Strazzabosco M
    Liver Int; 2017 Jul; 37(7):982-994. PubMed ID: 27943549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
    Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
    Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
    Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection.
    Nguyen J; Barritt AS; Jhaveri R
    J Pediatr; 2019 Apr; 207():90-96. PubMed ID: 30738661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit.
    Selvapatt N; Ward T; Harrison L; Lombardini J; Thursz M; McEwan P; Brown A
    Liver Int; 2017 Mar; 37(3):345-353. PubMed ID: 27566283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of expanding HCV screening and treatment policies in the United States.
    Linthicum MT; Gonzalez YS; Mulligan K; Moreno GA; Dreyfus D; Juday T; Marx SE; Lakdawalla DN; Edlin BR; Brookmeyer R
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP227-35. PubMed ID: 27266953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.
    Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DMS; Chung RT; Chhatwal J
    Clin Gastroenterol Hepatol; 2018 Jan; 16(1):115-122.e10. PubMed ID: 28634131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the cost-effectiveness of hepatitis C screening strategies in France.
    Deuffic-Burban S; Huneau A; Verleene A; Brouard C; Pillonel J; Le Strat Y; Cossais S; Roudot-Thoraval F; Canva V; Mathurin P; Dhumeaux D; Yazdanpanah Y
    J Hepatol; 2018 Oct; 69(4):785-792. PubMed ID: 30227916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection.
    Chaillon A; Mehta SR; Hoenigl M; Solomon SS; Vickerman P; Hickman M; Skaathun B; Martin NK
    PLoS One; 2019; 14(6):e0217964. PubMed ID: 31170246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treating Medicaid patients with hepatitis C: clinical and economic impact.
    Younossi Z; Gordon SC; Ahmed A; Dieterich D; Saab S; Beckerman R
    Am J Manag Care; 2017 Feb; 23(2):107-112. PubMed ID: 28245654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
    Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
    Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
    Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC
    Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.
    Chhatwal J; Chen Q; Ayer T; Bethea ED; Kanwal F; Kowdley KV; Wang X; Roberts MS; Gordon SC
    Aliment Pharmacol Ther; 2018 Apr; 47(7):1023-1031. PubMed ID: 29377245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis.
    Mattingly TJ; Slejko JF; Onukwugha E; Perfetto EM; Kottilil S; Mullins CD
    Pharmacoeconomics; 2020 Feb; 38(2):233-242. PubMed ID: 31788751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
    Scott N; Iser DM; Thompson AJ; Doyle JS; Hellard ME
    J Gastroenterol Hepatol; 2016 Apr; 31(4):872-82. PubMed ID: 26514998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
    Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
    Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses.
    Hagan LM; Yang Z; Ehteshami M; Schinazi RF
    J Viral Hepat; 2013 Dec; 20(12):847-57. PubMed ID: 24304454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
    Elbasha EH; Chhatwal J; Ferrante SA; El Khoury AC; Laires PA
    Appl Health Econ Health Policy; 2013 Feb; 11(1):65-78. PubMed ID: 23355388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States.
    Tatar M; Keeshin SW; Mailliard M; Wilson FA
    JAMA Netw Open; 2020 Sep; 3(9):e2015756. PubMed ID: 32880650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.